Enable Injections, Inc., a Cincinnati-based global healthcare innovation company, has successfully raised $30.0 million in new investment capital from investors. This significant funding round is set to bolster the company's ongoing efforts in developing and manufacturing advanced drug delivery systems designed to enhance the patient experience.
Enable Injections specializes in its body-worn enFuse® system, which is designed to deliver large-volume therapeutics via subcutaneous administration. This technology aims to enhance convenience for patients, potentially support improved safety outcomes, and contribute to advancements in healthcare system economics. The enFuse System has received device marketing authorizations from several ex-U.S. regulatory authorities, and a combination product approval with a specific drug has been granted in the U.S.
The $30.0 million capital infusion marks a pivotal moment for Enable Injections as it continues to advance its proprietary drug delivery technology. The company plans to strategically deploy these funds to scale its manufacturing capabilities, ensuring it can meet growing demand for its innovative solutions. Additionally, the investment will support expanded commercialization efforts, allowing Enable Injections to reach more patients and healthcare providers globally, and further develop its product pipeline to introduce new advancements. This investment underscores continued confidence in Enable Injections' approach to addressing critical unmet needs in drug administration.
This substantial financial backing is expected to significantly accelerate Enable Injections' growth trajectory, enabling the company to broaden its market reach and deepen its impact within the global healthcare sector. The company remains steadfast in its commitment to driving innovation and improving patient care through the continued development and deployment of advanced, user-friendly drug delivery solutions.
.png&w=3840&q=75)
